

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 21 U.S.C. 355(n)(4)

Peter Adamson, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: May 9, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to New Drug Application Junovan (mifamurtide), formerly known as (L-MTP-PE, liposomal muramyl tripeptide phosphatidyl ethanolamine), sponsored by IDM Pharma, Inc., for treatment of high-grade resectable non-metastatic osteosarcoma in combination with adjuvant chemotherapy for osteosarcoma. Genzyme Corporation, NOF Corporation, Ben Venue Laboratories, owned by Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, and Solvias AG are the contract manufacturers of the liposomal formulation of muramyl tripeptide phosphatidyl-ethanolamine. I am eligible to receive a waiver under 21 U.S.C. 355(n)(4).

| Type of Interest | Nature | Magnitude |
|------------------|----------------|-------------------------|
| Stock | Competing firm | Worth less than \$5,001 |

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

 / S /
Signature of SGE

 4/18/07
Date